Sun protection product developer Nanosive has been launched by Truffle Capital with a licence from Yale University.

The newly-founded Oxford cardiovascular imaging spinout raised seed funding from backers including Oxford Sciences Innovation to pursue further product development.

The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

Innovatus agreed to invest up to $42m in Personal Genome Diagnostics, whose existing backers include Bristol Myers-Squibb, Helsinn and Inova Health System.

Brain health product developer Accera has rebranded to Cerecin with a $50m round led by Wilmar International.

Immunometabolic drug developer Sitryx has closed a series A round featuring GlaxoSmithKline, after taking part in the latter's Immunology Network initiative.

Université libre de Bruxelles has added a fourth Theodorus fund to its arsenal with an initial close of $23m and a target of up to $33.5m.

Bsense Bio Therapeutics has emerged from stealth with a round of undisclosed size that involved Takeda Ventures and Johnson & Johnson Innovation–JJDC.

GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.